Cargando…
Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction
Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605508/ https://www.ncbi.nlm.nih.gov/pubmed/36294918 http://dx.doi.org/10.3390/life12101483 |
_version_ | 1784818084713857024 |
---|---|
author | Hintschich, Constantin A. Dietz, Melanie Haehner, Antje Hummel, Thomas |
author_facet | Hintschich, Constantin A. Dietz, Melanie Haehner, Antje Hummel, Thomas |
author_sort | Hintschich, Constantin A. |
collection | PubMed |
description | Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysically assessed the effect of intranasally applied mometasone furoate on the recovery of olfaction. The spray was applied with a long applicator so that the olfactory cleft could be reached effectively. After olfactory dysfunction had been confirmed psychophysically using Sniffin’ Sticks, patients were randomly assigned to two different treatment arms: the study group (n = 40) underwent olfactory training and intranasal administration of mometasone furoate twice daily, whereas the control group (n = 46) performed olfactory training only. After a study duration of three months, psychophysical testing of olfaction was repeated using Sniffin’ Sticks. We found no benefit of an additional topical administration of mometasone furoate compared to olfactory training alone. These results psychophysically confirm two previous studies which were based on patients’ subjective self-ratings. Our findings are in contrast to current recommendations for the management of olfactory dysfunction post-COVID-19, which might have to be adapted accordingly. |
format | Online Article Text |
id | pubmed-9605508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96055082022-10-27 Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction Hintschich, Constantin A. Dietz, Melanie Haehner, Antje Hummel, Thomas Life (Basel) Article Persistent olfactory dysfunction is a major concern post-COVID-19, affecting up to 5% of all patients. Different therapeutic options, including mometasone nasal spray, have been recommended, only some of which have been validated for post-COVID-19 olfactory dysfunction. In this study we psychophysically assessed the effect of intranasally applied mometasone furoate on the recovery of olfaction. The spray was applied with a long applicator so that the olfactory cleft could be reached effectively. After olfactory dysfunction had been confirmed psychophysically using Sniffin’ Sticks, patients were randomly assigned to two different treatment arms: the study group (n = 40) underwent olfactory training and intranasal administration of mometasone furoate twice daily, whereas the control group (n = 46) performed olfactory training only. After a study duration of three months, psychophysical testing of olfaction was repeated using Sniffin’ Sticks. We found no benefit of an additional topical administration of mometasone furoate compared to olfactory training alone. These results psychophysically confirm two previous studies which were based on patients’ subjective self-ratings. Our findings are in contrast to current recommendations for the management of olfactory dysfunction post-COVID-19, which might have to be adapted accordingly. MDPI 2022-09-24 /pmc/articles/PMC9605508/ /pubmed/36294918 http://dx.doi.org/10.3390/life12101483 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hintschich, Constantin A. Dietz, Melanie Haehner, Antje Hummel, Thomas Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title | Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title_full | Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title_fullStr | Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title_full_unstemmed | Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title_short | Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction |
title_sort | topical administration of mometasone is not helpful in post-covid-19 olfactory dysfunction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605508/ https://www.ncbi.nlm.nih.gov/pubmed/36294918 http://dx.doi.org/10.3390/life12101483 |
work_keys_str_mv | AT hintschichconstantina topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction AT dietzmelanie topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction AT haehnerantje topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction AT hummelthomas topicaladministrationofmometasoneisnothelpfulinpostcovid19olfactorydysfunction |